|
US20030152622A1
(en)
*
|
2001-10-25 |
2003-08-14 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral diuretic
|
|
US20030091630A1
(en)
*
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
|
PT1492511E
(pt)
|
2002-04-09 |
2009-04-09 |
Flamel Tech Sa |
Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
|
|
WO2004062623A2
(en)
|
2003-01-13 |
2004-07-29 |
Dynogen Pharmaceuticals, Inc. |
Method of treating functional bowel disorders
|
|
EP1589966B1
(en)
*
|
2003-01-30 |
2010-11-10 |
LEK Pharmaceuticals d.d. |
Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods
|
|
BRPI0406987A
(pt)
*
|
2003-01-31 |
2006-01-10 |
Sankyo Co |
Medicamento para a prevenção e/ou tratamento de arteriosclerose, medicamentos para a inibição de proliferação de células do músculo liso vascular, de formação de neoìntima dos vasos sanguìneos e de remodelação vascular, medicamento para a prevenção de restenose que segue intervenção coronária percutânea, e, medicamentos para a profilaxia e/ou tratamento de hipertensão ou doenças causadas por hipertensão ou doenças causadas por hipertensão, de doenças cardìacas, de angina do peito, de infarto miocárdico, de arritmia, de morte súbita, de insuficiência cardìaca, de hipertrofia cardìaca, de doenças renais, de nefropatia diabética, de glomerulonefrite, de nefrosclerose, de doenças cerebrovasculares, de infarto cerebral, e de hemorragia cerebral
|
|
WO2005079752A2
(en)
*
|
2004-02-11 |
2005-09-01 |
Rubicon Research Private Limited |
Controlled release pharmaceutical compositions with improved bioavailability
|
|
US7838552B2
(en)
*
|
2004-06-04 |
2010-11-23 |
Forest Laboratories Holdings Limited |
Compositions comprising nebivolol
|
|
US8022086B2
(en)
*
|
2004-10-29 |
2011-09-20 |
Kowa Co., Ltd. |
Therapeutic agent for glomerular disease
|
|
FR2884145A1
(fr)
*
|
2005-04-06 |
2006-10-13 |
Flamel Technologies Sa |
Forme pharmaceutique orale de losartan
|
|
FR2882260A1
(fr)
*
|
2005-02-21 |
2006-08-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
|
|
WO2006087394A1
(fr)
*
|
2005-02-21 |
2006-08-24 |
Flamel Technologies |
Forme pharmaceutique orale de losartan
|
|
EP1898951B1
(en)
*
|
2005-06-27 |
2013-02-27 |
Daiichi Sankyo Company, Limited |
Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
|
|
DE102005031577A1
(de)
|
2005-07-06 |
2007-01-11 |
Bayer Healthcare Ag |
Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
|
|
ES2383822T3
(es)
|
2005-07-11 |
2012-06-26 |
Cortria Corporation |
Formulaciones para el tratamiento de anomalías de lipoproteínas que comprenden una estatina y un derivado de metilnicotinamida
|
|
TWI399223B
(zh)
*
|
2006-09-15 |
2013-06-21 |
Daiichi Sankyo Co Ltd |
奧美沙坦酯及氨氯地平之固體劑型
|
|
KR100888131B1
(ko)
*
|
2006-10-10 |
2009-03-11 |
한올제약주식회사 |
시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
|
|
WO2009084040A1
(en)
*
|
2007-12-28 |
2009-07-09 |
Rubicon Research Private Limited |
Once a day formulation of angiotensin receptor blockers
|
|
US8372432B2
(en)
|
2008-03-11 |
2013-02-12 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
|
CN102105136B
(zh)
|
2008-03-11 |
2014-11-26 |
蒂宝制药公司 |
包含非-阿片类止痛剂和阿片类止痛剂的组合的胃滞留型缓释剂型
|
|
KR101209319B1
(ko)
|
2008-04-29 |
2012-12-06 |
한올바이오파마주식회사 |
안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
|
|
AR073380A1
(es)
|
2008-09-25 |
2010-11-03 |
Takeda Pharmaceutical |
Composicion farmaceutica solida. comprimido multicapa
|
|
DE102008059206A1
(de)
|
2008-11-27 |
2010-06-10 |
Bayer Schering Pharma Aktiengesellschaft |
Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
|
|
JP2012526133A
(ja)
|
2009-05-05 |
2012-10-25 |
ベイポジェニックス インコーポレイテッド |
炎症を低減させるための新規揮発性麻酔薬製剤およびその使用法
|
|
US8597681B2
(en)
|
2009-12-22 |
2013-12-03 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
|
US9198861B2
(en)
|
2009-12-22 |
2015-12-01 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
|
EP2392318A1
(en)
|
2010-05-21 |
2011-12-07 |
Laboratorios Liconsa, S.A. |
A pharmaceutical controlled release composition of losartan
|
|
CA2807661C
(en)
|
2010-08-11 |
2019-09-10 |
Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine |
Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
|
|
WO2012078633A2
(en)
|
2010-12-07 |
2012-06-14 |
Philadelphia Health And Education Corporation, D/B/A Drexel University College Of Medicene |
Methods of inhibiting metastasis from cancer
|
|
US8476221B2
(en)
|
2011-03-18 |
2013-07-02 |
Halimed Pharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders
|
|
US8858963B1
(en)
|
2011-05-17 |
2014-10-14 |
Mallinckrodt Llc |
Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
|
|
US9050335B1
(en)
|
2011-05-17 |
2015-06-09 |
Mallinckrodt Llc |
Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
|
|
US8741885B1
(en)
|
2011-05-17 |
2014-06-03 |
Mallinckrodt Llc |
Gastric retentive extended release pharmaceutical compositions
|
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
|
JP5977837B2
(ja)
|
2011-12-21 |
2016-08-24 |
ノヴィラ・セラピューティクス・インコーポレイテッド |
Ｂ型肝炎抗ウイルス剤
|
|
JP6231553B2
(ja)
|
2012-05-07 |
2017-11-15 |
バイエル ファーマ アクチエンゲゼルシャフト |
ニフェジピンおよびカンデサルタン・シレキセチルを含む医薬投与形を製造する方法
|
|
US9388126B2
(en)
|
2012-07-19 |
2016-07-12 |
Drexel University |
Sigma receptor ligands and methods of modulating cellular protein homeostasis using same
|
|
EP2950790A4
(en)
|
2012-08-09 |
2018-04-25 |
Dynamis Therapeutics, Inc. |
Methods for maintaining or improving health, well-being and/or a physiological function in a subject
|
|
SI2941233T1
(sl)
|
2013-01-07 |
2021-01-29 |
The Trustees Of The University Of Pennsylvania |
Sestavki in postopki za zdravljenje kutanega T celičnega limfoma
|
|
US10166207B2
(en)
|
2013-06-05 |
2019-01-01 |
Synchroneuron, Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
|
AU2014284267B2
(en)
|
2013-07-02 |
2018-05-10 |
Ecoplanet Environmental Llc |
Volatile organic compound formulations having antimicrobial activity
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
WO2015028972A1
(en)
|
2013-09-02 |
2015-03-05 |
Ranbaxy Laboratories Limited |
Pulsatile-release dosage form
|
|
ES2806027T3
(es)
|
2013-11-26 |
2021-02-16 |
Univ Yale |
Nuevas composiciones penetrantes de células y métodos de uso de las mismas
|
|
US9867833B2
(en)
|
2013-12-06 |
2018-01-16 |
Genentech, Inc. |
Serine/threonine kinase inhibitors
|
|
WO2015089049A1
(en)
|
2013-12-09 |
2015-06-18 |
Thomas Jefferson University |
Novel methods of treating a neurodegenerative disease in a mammal in need thereof
|
|
US9982010B2
(en)
|
2014-04-07 |
2018-05-29 |
Women & Infants Hospital Of Rhode Island |
7-dehydrocholesterol derivatives and methods using same
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
CA2968215A1
(en)
|
2014-08-20 |
2016-02-25 |
Yale University |
Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
|
|
WO2016182968A1
(en)
|
2015-05-08 |
2016-11-17 |
Brown University |
Novel syringolin analogues and methods of making and using same
|
|
WO2016187408A1
(en)
|
2015-05-19 |
2016-11-24 |
Yale University |
Compositions for treating pathological calcification conditions, and methods using same
|
|
US10829440B2
(en)
|
2015-06-12 |
2020-11-10 |
Brown University |
Antibacterial compounds and methods of making and using same
|
|
US10294228B2
(en)
|
2015-06-30 |
2019-05-21 |
Neurad Ltd. |
Breathing control modulating compounds, and methods of making and using same
|
|
CN108135886A
(zh)
*
|
2015-07-29 |
2018-06-08 |
塔科达有限责任公司 |
用于糖尿病性肾病治疗的pde4抑制剂
|
|
JP6970667B2
(ja)
|
2015-10-28 |
2021-11-24 |
イエール ユニバーシティ |
キノリンアミドおよびその使用法
|
|
WO2017087936A1
(en)
|
2015-11-20 |
2017-05-26 |
Yale University |
Compositions for treating ectopic calcification disorders, and methods using same
|
|
US9687475B1
(en)
|
2016-03-24 |
2017-06-27 |
Ezra Pharma Llc |
Extended release pharmaceutical formulations with controlled impurity levels
|
|
US9675585B1
(en)
|
2016-03-24 |
2017-06-13 |
Ezra Pharma |
Extended release pharmaceutical formulations
|
|
EP3448369B1
(en)
|
2016-04-29 |
2025-06-25 |
The Regents of The University of Colorado, A Body Corporate |
Inhibition or degradation of hdac11 for treating obesity, hyperlipidemia, type ii diabetes, metabolic syndrome or insulin resistance, for promoting weight loss, and/or ameliorating or preventing weight gain
|
|
WO2018026764A1
(en)
|
2016-08-01 |
2018-02-08 |
University Of Rochester |
Nanoparticles for controlled release of anti-biofilm agents and methods of use
|
|
WO2018027024A1
(en)
|
2016-08-05 |
2018-02-08 |
Yale University |
Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
|
|
US10683283B2
(en)
|
2016-09-01 |
2020-06-16 |
Mebias Discovery, Inc. |
Substituted ureas and methods of making and using same
|
|
KR102522060B1
(ko)
|
2016-11-07 |
2023-04-14 |
아뷰터스 바이오파마 코포레이션 |
치환된 피리디논 함유 트리시클릭 화합물, 및 그의 사용 방법
|
|
EP4219486A1
(en)
|
2017-01-19 |
2023-08-02 |
Temple University of the Commonwealth System of Higher Education |
Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use
|
|
CA3056886A1
(en)
|
2017-03-21 |
2018-09-27 |
Arbutus Biopharma Corporation |
Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
|
|
JP7108018B2
(ja)
|
2017-04-17 |
2022-07-27 |
イエール ユニバーシティ |
急性肺傷害を処置または予防する化合物、組成物および方法
|
|
EP3659307A4
(en)
|
2017-07-28 |
2021-09-22 |
Yale University |
ANTI-CANCER PRODUCTS AND METHOD FOR MANUFACTURING AND USING THEREOF
|
|
CA3074017A1
(en)
|
2017-09-08 |
2019-03-14 |
The Regents Of The University Of Colorado, A Body Corporate |
Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers
|
|
US20200323895A1
(en)
|
2017-11-27 |
2020-10-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic |
Compounds, Compositions, and Methods for Treating And/Or Preventing Periodontal Disease
|
|
US11337920B2
(en)
|
2017-12-18 |
2022-05-24 |
Tris Pharma, Inc. |
Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
|
|
CA3085941A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
|
|
CA3086153A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
|
|
WO2019125184A1
(en)
|
2017-12-19 |
2019-06-27 |
Auckland Uniservices Limited |
Use of biomarker in cancer therapy
|
|
CA3089236A1
(en)
|
2018-01-24 |
2019-08-01 |
The Rockefeller University |
Antibacterial compounds, compositions thereof, and methods using same
|
|
EP3802572A4
(en)
|
2018-05-25 |
2022-03-23 |
Temple University - Of The Commonwealth System of Higher Education |
REMOVAL OF BACTERIAL BIOFILM USING ANTI-AMYLOID MONOCLONAL ANTIBODIES
|
|
JP2021525269A
(ja)
|
2018-05-29 |
2021-09-24 |
セルシィ セラピューティクス，インコーポレーテッド |
疼痛処置のための化合物、それを含む組成物及びそれを使用する方法
|
|
TWI826492B
(zh)
|
2018-07-27 |
2023-12-21 |
加拿大商愛彼特生物製藥公司 |
經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
|
|
CA3109798A1
(en)
|
2018-08-17 |
2020-02-20 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of acute lung injury
|
|
AU2018445164B2
(en)
|
2018-10-11 |
2025-05-29 |
Vifor (International) Ltd. |
Inositol phosphates for the treatment of ectopic calcification
|
|
US12458601B2
(en)
|
2018-10-19 |
2025-11-04 |
Temple University-Of The Commonwealth System Of Higher Education |
Tamper-resistant drug dosage forms and methods of making and use thereof
|
|
TW202415643A
(zh)
|
2018-12-12 |
2024-04-16 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
|
BR112021014897A2
(pt)
|
2019-01-30 |
2021-09-28 |
Sanifit Therapeutics, S.A. |
Composto ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
|
|
US20200246316A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
|
|
US20200246317A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
|
|
US11471507B2
(en)
|
2019-05-09 |
2022-10-18 |
The Feinstein Institutes For Medical Research |
HMGB1 antagonist
|
|
EP3983391A4
(en)
|
2019-06-12 |
2023-06-28 |
The Wistar Institute |
Acetyl-coa synthetase 2 (acss2) inhibitors and methods using same
|
|
US11555010B2
(en)
|
2019-07-25 |
2023-01-17 |
Brown University |
Diamide antimicrobial agents
|
|
EP3818983A1
(en)
|
2019-11-11 |
2021-05-12 |
Sanifit Therapeutics S.A. |
Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
|
|
WO2021127456A1
(en)
|
2019-12-19 |
2021-06-24 |
Rain Therapeutics Inc. |
Methods of inhibiting epidermal growth factor receptor proteins
|
|
JP2023529892A
(ja)
|
2020-06-09 |
2023-07-12 |
イノザイム ファーマ インク． |
可溶性ｅｎｐｐ１又はｅｎｐｐ３タンパク質及びその使用
|
|
EP4015494A1
(en)
|
2020-12-15 |
2022-06-22 |
Sanifit Therapeutics S.A. |
Processes for the preparation of soluble salts of inositol phosphates
|
|
EP4036097A1
(en)
|
2021-01-29 |
2022-08-03 |
Sanifit Therapeutics S.A. |
Ip4-4,6 substituted derivative compounds
|
|
JP2025525092A
(ja)
|
2022-07-29 |
2025-08-01 |
サニフィット・セラピューティクス・ソシエダッド・アノニマ |
異所性石灰化の治療、進行の阻害、および予防に使用するためのｉｐ４－４，６置換誘導体化合物
|
|
TW202412815A
(zh)
|
2022-07-29 |
2024-04-01 |
西班牙商薩尼菲特治療公司 |
Ip5經取代化合物
|
|
WO2024052895A1
(en)
|
2022-09-06 |
2024-03-14 |
Hadasit Medical Research Services And Development Ltd |
Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders
|
|
TW202513071A
(zh)
|
2023-08-14 |
2025-04-01 |
以色列商琉璃藥品 (1991) 有限公司 |
Gal475組合物及其使用方法
|
|
WO2025162971A1
(en)
|
2024-01-31 |
2025-08-07 |
Sanifit Therapeutics, S.A. |
Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
|
|
WO2025217094A1
(en)
|
2024-04-08 |
2025-10-16 |
University Of Rochester |
Interleukin receptor-associated kinase (irak) protac degraders and medical use thereof
|
|
WO2025217096A1
(en)
|
2024-04-08 |
2025-10-16 |
University Of Rochester |
Inhibitors of leucine-rich repeat kinase 2 (lrrk2) and medical uses thereof
|
|
WO2025217379A1
(en)
|
2024-04-10 |
2025-10-16 |
University Of Rochester |
Drug treatment for macular degeneration
|